Tsutomu Nakagawa
Direttore/Membro del Consiglio presso SUMITOMO PHARMA CO., LTD.
Posizioni attive di Tsutomu Nakagawa
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| SUMITOMO PHARMA CO., LTD. | Direttore/Membro del Consiglio | 25/06/2024 | - |
| Corporate Officer/Principal | 01/04/2016 | - | |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Direttore/Membro del Consiglio | 01/07/2023 | - |
| Amministratore Delegato | 01/04/2024 | - | |
| Presidente | 01/04/2024 | - | |
| Corporate Officer/Principal | 01/07/2023 | 01/04/2024 |
Storia della carriera di Tsutomu Nakagawa
Statistiche
Distribuzione geografica
| Stati Uniti | 2 |
| Giappone | 2 |
Posizioni
| Director/Board Member | 2 |
| Corporate Officer/Principal | 2 |
| Chief Executive Officer | 1 |
Settori
| Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SUMITOMO PHARMA CO., LTD. | Health Technology |
| Aziende private | 1 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Health Technology |
- Borsa valori
- Insiders
- Tsutomu Nakagawa
- Esperienza
